Literature DB >> 20956871

[Study on in-vitro susceptibility of ESBL-positive Escherichia coli isolated from urine specimens].

Stefano Grandesso1, Barbara Sapino, Sandra Mazzucato, Roberta Alessandrini, Maria Solinas, Massimo Gion.   

Abstract

Treatment of infections by beta-lactamase-producing microorganisms is very difficult. Our aim was to determine the in vitro susceptibility of 430 ESBL-positive Escherichia coli strains isolated from urinary tract infections. All the microorganisms were isolated in the Microbiology Unit at the Ospedale dell'Angelo in Mestre (Venice) between May 2008 and September 2009 and were confirmed by the double-disk test. All microorganisms were sensitive to imipenem and meropenem, 98.4% to tigecycline, 95.1% to amikacin, 89.3% to nitrofurantoin, 67.5% to gentamycin and 63.2% to piperacillin/tazobactam. Only 22.6% were sensitive to cotrimoxazole, while fluoroquinolone (norfloxacin and levofloxacin) activity was found to be very low (6%).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956871

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  1 in total

1.  The antibacterial effect of nitric oxide against ESBL-producing uropathogenic E. coli is improved by combination with miconazole and polymyxin B nonapeptide.

Authors:  Charlotte Sahlberg Bang; Annica Kinnunen; Marie Karlsson; Anna Önnberg; Bo Söderquist; Katarina Persson
Journal:  BMC Microbiol       Date:  2014-03-14       Impact factor: 3.605

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.